[A19-08] Brigatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Last updated 15.04.2019
Commission awarded on 15.01.2019 by the Federal Joint Committee (G-BA).
Adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
Added benefit not proven due to lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.